Skip to contentS
Sanara MedTech Inc.
S
SMTISanara MedTech Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$26.31M$26.31Mderived+48.7% vs Q4 2023 Net Income-$1.54M-$1.54MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sanara MedTech Inc. · CIK 714256 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$24,056,183+51.3% Operating Incomederived$4,896,867N/M Operating Cash Flowderived$932,047N/M Free Cash Flowderived$859,875N/M Margins · derivedGross margin91.4%+1.6 pt vs Q4 2023
Operating margin18.6%+19.9 pt vs Q4 2023
Net margin-5.8%−4.5 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 25, 2025 · 84 d after period end